WCC Plan B OTC Marketing Partnership Sought Pending Switch Approval
This article was originally published in The Tan Sheet
Executive Summary
Women's Capital Corporation "is in discussions with a number of potential strategic marketers" to sell an OTC version of its Plan B emergency contraceptive pending approval of the firm's April 21 switch application
You may also be interested in...
Plan B Behind-The-Counter Status Discouraged By Panel Members
Barr Labs' Plan B (levonorgestrel) emergency contraceptive was recommended for over-the-counter in a 23-4 vote by the Nonprescription Drugs and Reproductive Health Drugs Advisory Committees at a joint meeting Dec. 16 in Gaithersburg, Md. The joint panel rejected behind-the-counter status for the product
Plan B Mechanism Of Action At The Heart Of Panel Labeling Debate
Women who are considering using Barr Laboratories' Plan B (levonorgestrel .75 mg) should know the drug's mechanism of action at the point of purchase, according to FDA advisory committee panelists
Barr Plans Move To OTC Market With Plan B Emergency Contraceptive
Barr Laboratories will continue to pursue an Rx-to-OTC switch for the emergency contraceptive Plan B following its planned acquisition of the product